EVALUATION OF THE THERAPEUTIC SUPPORT EFFECTS OF LIGHT THERAPY FOR PATIENTS WITH SEVERE ACNE VULGARIS

Abstract

Objective: To evaluate the treatment results of combined blue light (415 nm wavelength) and red light (633 nm wavelength) therapy for patients with severe acne vulgaris. Subjects and methods: A pre-post comparative interventional study on 30 patients with severe acne vulgaris, examined and treated at the Central Dermatology Hospital from July 2022 to June, 2023. Results: The female-to-male patient ratio was approximately 2.3/1. Patients aged 16-25 accounted for 70.8%, and 46.7% had family members with acne. Clinically, 100% of patients had facial lesions (with 97.8% of lesions in the cheek area). The number of inflammatory and non-inflammatory lesions gradually decreased from week four to week 12 of treatment. The differences between treatment weeks and pre-treatment were statistically significant, with p < 0.05. Good and very good treatment results increased for both genders after four, eight, and 12 weeks of the treatment, with statistically significant changes (p1-2 < 0.05 and p3-1 < 0.05). Dry lips remained a common unwanted effect at the end of treatment (60.0%). Conclusions: Treatment of severe acne vulgaris with isotretinoin combined with blue light and red light had a good treatment effect after 12 weeks of treatment.